ArticleFrontiers in immunology2023

Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.

Thomas Dudler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.